Dachaigh › Paraganglioma › Maryland
Sgrùdaidhean clionaigeach Paraganglioma ann an Maryland
Tha 7 sgrùdaidhean airson Paraganglioma a’ lorg phàirtichean aig làraichean ann an Maryland.
Teacsa sgrùdaidh oifigeil (Beurla)
[212Pb]VMT-Alpha-NET in Metastatic or Inoperable Somatostatin-Receptor Positive Gastrointestinal Neuroendocrine Tumors, Pheochromocytoma/Paragangliomas, Small Cell Lung, Renal Cell, and Head and Neck Cancers
- National Institutes of Health Clinical Center, Bethesda
A’ fastadhÌre 1
Aoisean 18 gu 120 · Gach gnè · Air ùrachadh 2 Dàmh 2026 · NCT06479811Belzutifan/MK-6482 for the Treatment of Advanced Pheochromocytoma/Paraganglioma (PPGL), Pancreatic Neuroendocrine Tumor (pNET), Von Hippel-Lindau (VHL) Disease-Associated Tumors, Advanced Gastrointestinal Stromal Tumor (wt GIST), or Solid Tumors With HIF-2α Related Genetic Alterations (MK-6482-015)
- Johns Hopkins Hospital-Sidney Kimmel Comprehensive Cancer Center - Developmental Therapeutics ( Site 0108), Baltimore
- National Institutes of Health ( Site 0125), Bethesda
A’ fastadhÌre 2
Aoisean 12 agus nas sine · Gach gnè · Air ùrachadh 25 Sult 2026 · NCT04924075Lu-177-DOTATATE (Lutathera) in Therapy of Inoperable Pheochromocytoma/ Paraganglioma
- National Institutes of Health Clinical Center, Bethesda
A’ fastadhÌre 2
Aoisean 18 gu 100 · Gach gnè · Air ùrachadh 25 Lùna 2026 · NCT03206060Somatostatin-Receptors (SSTR)-Agonist [212Pb]VMT-alpha-NET in Metastatic or Inoperable SSTR+ Gastrointestinal Neuroendocrine Tumor and Pheochromocytoma/Paraganglioma Previously Treated With Systemic Targeted Radioligand Therapy
- National Institutes of Health Clinical Center, Bethesda
A’ fastadhÌre 1/2
Aoisean 18 gu 120 · Gach gnè · Air ùrachadh 18 Lùna 2026 · NCT06427798A First-in-Human Phase I Trial With Antibody Drug Conjugate ADCT-701 in Neuroendocrine Tumors, Carcinomas and Malignant Peripheral Nerve Sheath Tumors
- National Institutes of Health Clinical Center, Bethesda
A’ fastadhÌre 1
Aoisean 18 gu 120 · Gach gnè · Air ùrachadh 15 Ògmh 2026 · NCT0604151618F-Fibroblast Activation Protein Inhibitor ([18F]FAPI-74) PET Imaging for Cancer Detection
- National Institutes of Health Clinical Center, Bethesda
A’ fastadhÌre 2
Aoisean 18 gu 120 · Gach gnè · Air ùrachadh 19 Cèit 2026 · NCT06503146Targeted Alpha-Particle Therapy for Advanced Somatostatin Receptor Type 2 (SSTR2) Positive Tumors
- Johns Hopkins, Baltimore
A’ fastadhÌre 1/2
Aoisean 18 gu 90 · Gach gnè · Air ùrachadh 14 Cèit 2026 · NCT05636618Bho ClinicalTrials.gov, dàta air a thogail 5 Dàmh 2026. Bidh gach sgrùdadh a’ suidheachadh a chuidi fhèin; bidh an sgioba sgrùdaidh a’ co-dhùnadh cò as urrainn pàirt a ghabhail.